We have constructed a panel of substitution mutants which affect one o
r more of the putative cdk target sites of the RB protein. We have exa
mined the activity of these mutants relative to wild-type RB by both a
transcriptional repression assay and by measuring growth suppression
in vitro. We find that some phosphorylation site mutants of pRB can re
press E2 transcription more strongly than wild-type RB. These mutants
are partially resistant to phosphorylation by cdks and can arrest tumo
r cells in G1 in vitro. Our results indicate a functional correlation
between the ability to repress E2F-dependent transcription and the abi
lity to suppress tumor cell growth in vitro. In addition, we describe
two classes of RB mutants: N-terminal truncated p56(RB) and a novel mu
tant of RB containing multiple substitutions near its nuclear localiza
tion signal. Both classes of RB mutants have greater activity than the
mild-type protein. Because RB is a key regulator of cell cycle progre
ssion, expression of a more potent, phosphorylation resistant RB may h
ave utility in both RB(-/-) and RB(+/+) tumors as well as in hyperprol
iferative disorders.